Various venom-derived drugs have been tested for their pharmacological abilities and are approved by the United States Food and Drug Administration, such as Ancrod as a defibrinogenating agent, Aggrastat as an anticoagulant, L-amino acid oxidase as an antibacterial agent, Nigexine as an antiviral agent, Captopril for hypertension by inhibiting angiotensin-converting enzyme (Vonk et al., 2011), Ximelagatran as a thrombin inhibitor, and Batroxobin to convert fibrinogen to fibrin (El-Aziz et al., 2019). This evidence concerns the gene IL4I1 and hypertensive disorder.